Chronomodulated Administration of Oxaliplatin plus Capecitabine (XELOX) as First Line Chemotherapy in Metastatic Colorectal Cancer Patients: Phase II Brunch Regimen Study.

Cancer Patients ◽

Phase Ii ◽

First Line ◽

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Cancer Research and Treatment ◽

10.4143/crt.2018.379 ◽

2019 ◽

Vol 51 (3) ◽

pp. 1128-1134

Author(s):

Youjin Kim ◽

Tae Won Kim ◽

Sae Won Han ◽

Joong Bae Ahn ◽

Seung Tae Kim ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Faculty Opinions recommendation of Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726943980.793538773 ◽

2017 ◽

Author(s):

Noelle LoConte ◽

Kieran Sahasrabudhe

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Iii ◽

First Line ◽

Phase Iii Study ◽

Genetic variants in the Folic acid Metabolic Pathway Genes predict outcomes of metastatic Colorectal Cancer patients receiving first-line Chemotherapy

Journal of Cancer ◽

10.7150/jca.44580 ◽

2020 ◽

Vol 11 (22) ◽

pp. 6507-6515

Author(s):

Lu Jiang ◽

Shuwei Li ◽

Ming Yuan ◽

Ling Ma ◽

Yu Lin ◽

...

Keyword(s):

Colorectal Cancer ◽

Folic Acid ◽

Cancer Patients ◽

Metabolic Pathway ◽

Genetic Variants ◽

First Line ◽

P-272 Sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy

Annals of Oncology ◽

10.1016/j.annonc.2020.04.354 ◽

2020 ◽

Vol 31 ◽

pp. S178

Author(s):

C. Maddalena ◽

A. Ponsiglione ◽

L. Camera ◽

L. Santarpia ◽

F. Pasanisi ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

First Line ◽

Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients

Annals of Oncology ◽

10.1093/annonc/mdy150.014 ◽

2018 ◽

Vol 29 ◽

pp. v97

Author(s):

V. Catalano ◽

F. Bergamo ◽

C. Cremolini ◽

B. Vincenzi ◽

F. Negri ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

First Line ◽

Combined Analysis ◽

Mucinous Histology ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

Colorectal Cancer Patients

Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials

Annals of Oncology ◽

10.1093/annonc/mdy281.091 ◽

2018 ◽

Vol 29 ◽

pp. viii182

Author(s):

C. Montagut ◽

V. Alonso ◽

P. Escudero ◽

C. Fernández-Martos ◽

A. Salud Salvia ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Trials ◽

Cancer Patients ◽

Braf Mutation ◽

Clinical Impact ◽

First Line ◽

Mutation Dynamics ◽

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

Annals of Oncology ◽

10.1093/annonc/mdy151.205 ◽

2018 ◽

Vol 29 ◽

pp. v57 ◽

Cited By ~ 1

Author(s):

G. Bruera ◽

S. Massacese ◽

F. Pepe ◽

U. Malapelle ◽

A. Dal Mas ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Wild Type ◽

First Line ◽

Triplet Chemotherapy ◽

Preliminary Phase

Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients

Korean Journal of Clinical Oncology ◽

10.14216/kjco.15010 ◽

2015 ◽

Vol 11 (2) ◽

pp. 51-58 ◽

Cited By ~ 1

Author(s):

Sang Hun Jung ◽

So Hyun Kim ◽

Jae Hwang Kim

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Clinical Correlation ◽

First Line ◽